The clinical study is a randomized, double-blind, two-arm, parallel group study that is expected to enroll approximately 182 healthy volunteers.
Each patient will receive a single subcutaneous dose of either BAT2506 or EU-sourced Simponi.
Bio-Thera Solutions is developing several additional proposed biosimilars, including biosimilar versions of Avastin and Actemra/RoActemra, which are both currently being evaluated in global Phase III clinical trials. Bio-Thera Solutions is also pursuing biosimilar versions of Humira and Stelara.
Bio-Thera Solutions, a biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial